Mor­phoSys files for $150M IPO to fu­el its hope­ful DL­B­CL drug launch

Mor­phoSys, a pub­lic com­pa­ny in Ger­many, is shoot­ing for a dual list­ing of its shares, hop­ing to raise $150 mil­lion by head­ing to the Nas­daq …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.